Search for other works by this author on: ...

University of Arkansas for Medical Sciences, Little Rock, AR, United States ...

Healthcare services company Cardinal Health will acquire Integrated Oncology Network (ION) for about $1.12 billion. A physician-led operator of community cancer centers, ION includes more than 50 ...

Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth. Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD ...

The development of second-generation covalent “off”-state KRAS G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with ...

Search for other works by this author on: ...

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.

Search for other works by this author on: ...

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

University of Nebraska Medical Center, Omaha, NE, ...